- Home
- BLDP vs MREO Comparison
BLDP vs MREO Comparison
Compare BLDP & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLDP
- MREO
- Stock Information
- Founded
- BLDP 1979
- MREO 2015
- Country
- BLDP Canada
- MREO United Kingdom
- Employees
- BLDP N/A
- MREO N/A
- Industry
- BLDP Industrial Machinery/Components
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- BLDP Energy
- MREO Health Care
- Exchange
- BLDP Nasdaq
- MREO Nasdaq
- Market Cap
- BLDP 446.1M
- MREO 482.5M
- IPO Year
- BLDP 1995
- MREO N/A
- Fundamental
- Price
- BLDP $1.40
- MREO $2.85
- Analyst Decision
- BLDP Hold
- MREO Strong Buy
- Analyst Count
- BLDP 11
- MREO 6
- Target Price
- BLDP $2.25
- MREO $7.83
- AVG Volume (30 Days)
- BLDP 9.7M
- MREO 917.3K
- Earning Date
- BLDP 03-13-2025
- MREO 03-26-2025
- Dividend Yield
- BLDP N/A
- MREO N/A
- EPS Growth
- BLDP N/A
- MREO N/A
- EPS
- BLDP N/A
- MREO N/A
- Revenue
- BLDP $91,962,000.00
- MREO $1,000,000.00
- Revenue This Year
- BLDP N/A
- MREO N/A
- Revenue Next Year
- BLDP $25.80
- MREO N/A
- P/E Ratio
- BLDP N/A
- MREO N/A
- Revenue Growth
- BLDP 24.01
- MREO N/A
- 52 Week Low
- BLDP $1.23
- MREO $2.53
- 52 Week High
- BLDP $3.38
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- BLDP 44.65
- MREO 38.17
- Support Level
- BLDP $1.42
- MREO $2.82
- Resistance Level
- BLDP $1.54
- MREO $2.99
- Average True Range (ATR)
- BLDP 0.08
- MREO 0.13
- MACD
- BLDP 0.02
- MREO 0.01
- Stochastic Oscillator
- BLDP 46.15
- MREO 14.74
About BLDP Ballard Power Systems Inc.
Ballard Power Systems Inc is a world leader in proton-exchange membrane fuel cells, power system development, and commercialization. The company's principal business is the design, development, manufacture, sale, and service of PEM fuel cell products for a variety of applications, focusing on power product markets of heavy-duty motive (bus, truck, rail, and marine applications), material handling, and stationary power generation. Sales are concentrated in the US, Europe, and China.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).